Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interferon-beta · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| Interferon-beta | GENETIC | - |
Inclusion Criteria: 1. Must be greater than or equal to 18 years of age. 2. Subjects must have histologically proven GBM, AA, AMO, malignant astrocytoma NOS or gliosarcoma and recurrent or progressive tumor following prior treatment. 3. Tumor must be amenable to radical resection, and resection mus...
Interferon-beta is being studied as a gene therapy for Glioblastoma Multiforme, a type of brain cancer. It is delivered through gene transfer to potentially treat the tumor. The therapy is in Phase 1 clinical development and remains investigational, meaning it has not been approved for use.
Interferon-beta is being developed by Biogen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker BIIB. The company is conducting clinical research on this gene therapy for Glioblastoma Multiforme.
Interferon-beta is in Phase 1 clinical development. It is an investigational gene therapy for Glioblastoma Multiforme and has not been approved by regulatory authorities. The Phase 1 trial has been completed.
Interferon-beta has one completed Phase 1 clinical trial, identified as NCT00031083. The study was a dose escalation trial to determine the safety of IFN-Beta gene transfer in the treatment of Grade III and Grade IV gliomas, including Glioblastoma Multiforme. It enrolled 12 participants in the United States.
Interferon-beta works through gene transfer, a method of delivering the interferon-beta gene into cells to produce the therapeutic protein. This approach is being evaluated for its safety in treating Glioblastoma Multiforme and other high-grade gliomas.
Yes, Interferon-beta is also known as IFN-Beta. The clinical trial NCT00031083 refers to the therapy as IFN-Beta gene transfer, and it is the same investigational gene therapy being developed by Biogen Inc. for Glioblastoma Multiforme.